Press Releases
Date picker
Category
Results per page
Kancera appoints Peter Selin as new Chief Executive Officer
Regulatory
Kancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as…
Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851
Regulatory
The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating…
Kancera reports start of patient screening for the KANDOVA-study
Kancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University…
Kancera has submitted application to conduct First-In-Human study of KAND145
Kancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.
The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145
Kancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.
Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023
Kancera AB (publ) today reports that the patient enrollment to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, has been completed and that a total…
Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851
Year in briefOctober – DecemberFinancial summary for the fourth quarterNet sales amounted to SEK 0 million (SEK 0.0 million).R&D costs amounted to SEK 11,6 million (12,9 million).Operating profit for the…
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
Kancera AB (publ) today reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study, a clinical study of KAND567 in ovarian cancer patients. The company…
Kancera provides operational update for its Fractalkine-blocking drug candidates KAND567 and KAND145
Kancera AB (publ) today reports that the clinical studies of its Fractalkine-blocking drug candidates KAND567 and KAND145 are progressing according to plans and that the US patent office has issued…
Kancera reports that the FRACTAL-study is on track to report top line results in Q3 2023
Kancera AB (publ) reports that 63 subjects have been recruited to the ongoing FRACTAL-study, a phase IIa study of KAND567 in myocardial infarction patients, which exceeds the initial objective of…